Clinical Genomics said this week that after seeing early success with a limited commercial roll out of its epigenetic colorectal cancer recurrence test Colvera that began in January, it now plans to launch the test more broadly this summer.
Unlike many genomic approaches now being advanced for blood-based cancer detection by companies like Guardant Health, Foundation Medicine, and more, Colvera is relatively simple: designed to detect the presence of epigenetic modifications of two genes — BCAT1 and IKZF1 — using PCR technology and reagents from Qiagen.
The assay is designed for a specific clinical niche, and with a simple proposition — that it outperforms the current gold standard for monitoring colorectal cancer patients after surgery.
For example, in a study published last fall in Cancer Medicine, company researchers concluded that Colvera picks up about twice the number of colorectal cancer recurrences as currently used blood tests that measure levels of carcinoembryonic antigen (CEA).
Early detection or screening in undiagnosed patients is not something that Clinical Genomics has in mind for the test, LaPointe said. There are already both stool- and blood-based tests for this niche — namely Exact Sciences’ ColoGuard fecal test and Epigenomics blood-based Epi proColon.
The ELP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: Clinical Genomics Planning Wider Launch of Colvera After Piloting in Local Markets